Background: To evaluate the feasibility and therapeutic effect of chemotherapy combined with regional radio frequency hyperthermia for pretreated locally advanced non-small cell lung cancer.
Background
Non-small cell lung cancer accounts for at least 80% of all lung neoplasma, and about 35% of these patients present with locally advanced unresectable disease [1] . Systemic chemotherapy with the platinum-containing regimens plus concurrent regional radiation is generally accepted as the standard first-line treatment for inoperable locally advanced non-small cell lung cancer, meta-analysis confirmed the response and survival benefits, but the large number of patients will experience disease progression or tumor relapse [2] [3] [4] [5] [6] . For patients with a good performance status, second-line chemotherapy is recommended. Several third-generation chemotherapeutic agents had been evaluated in the second line setting, docetaxel maybe the most extensively studied one [7] [8] [9] [10] . Recent studies indicated that second-line chemotherapy with docetaxel weekly as a single-agent regimen for pretreated non-small cell lung cancer was well tolerant and had an acceptable response rate and a reasonable median survival time about 26.1 weeks [7, 11, 12] . Obviously, neither physicians nor patients are satisfied with this.
Empirical studies indicated that heat played a lethal effect to human tumor cell lines, and heat enhanced cytotoxic effect of chemotherapeutics [13] [14] [15] . Along with the development of technology, hyperthermia improves therapeutic effect of superficial tumors, soft tissue sarcoma, osteosarcoma, prostate cancer, breast cancer and some recurrent or advanced solid tumors [16] [17] [18] [19] [20] [21] . There are rare reports that demonstrate the advantage of adding hyperthermia to chemotherapy as the second-line therapy for pretreated locally advanced non-small cell lung cancer. In present study, we combined docetaxel weekly chemotherapy with external regional radio frequency (RF) hyperthermia as the second-line treatment for patients with inoperable stage III non-small cell lung cancer who had failed to response to the prior platinum-containing chemotherapy. The toxicities and progression free survive (PFS) were primarily investigated.
Methods

Patients selection
Eligible patients must had histological or cytological proof to be inoperable stage IIIa or IIIb non-small cell lung cancer, and should have at least one measurable lesion. They experienced only one platinum-containing regimen as the first-line treatment, whether accompanied with irradiation or not. They failed to respond to the firstline treatment, and proved to be still inoperable by spiral computed tomograph. In addition, patients should be with a ECOG performance status ≤ 2, and have normal hematological index (neutrophil count ≥ 2 × 10 9 /l, platelet count ≥ 100 × 10 9 /l, haemoglobin ≥ 100 g/l) and acceptable biochemical analysis result (normal bilirubin level, alanine aminotransferase ≤ 2.5 × upper limit of normal (ULN) and serum creatinine level ≤ 1.5 × ULN). Patients with metal foreign matter, fever (≥ 38°C), significant hemorrhagic tendency, and seriously impaired function of lung or heart were excluded. Every patient enrolled in this study had signed a written informed consent form approved by Si Chuan University Hua Xi Medical Ethics Committee, which also approved the study protocol.
Chemotherapy regimen
A regimen of docetaxel 40 mg/m 2 intravenous infusion on day1, 8 and 15, repeated every 4 weeks was chosen. Docetaxel was administered intravenously within 1 hour. Prophylactic oral corticosteroid premedication (dexamethasone 8 mg) was given 3 times over 2 days. Target sum of chemotherapy would be 4 cycles. Dose adjustment should be done when grade 4 hematological or grade 3,4 non-hematological toxicities appeared, a dose reduction was of 25% in subsequent cycles. Docetaxel infusion could not be delayed for over 2 weeks since patient discontinuation.
Hyperthermia regimen
We used a radio frequency external heat system (Ho Kai company, China) working frequency was 13.8 MHz to perform regional hyperthermia. Primary lesion was chosen to be the target area, covered by an applicator 20 cm in diameter. Hyperthermia was administered 1 hour after chemotherapeutics were given, the total heated time was up to 60 minutes, twice a week, aimed to 32 times, interval between 2 procedures should exceed 48 hours. Target temperature ranged from 41°C to 43°C, we instructed every patient to mention any abnormal feelings, so that we could adjust settings such as power output, or place a water bolus to ease the uncomfortable.
Evaluation of response and toxicity
The response had been estimated within a week after every 2 cycles of chemotherapy were given, and to be confirmed in 4 weeks of responding patients. We used contrastenhanced spiral computed tomograph to measure the largest diameter of target tumor, response criteria was based on Response Evaluation Criteria In Solid Tumors (RECIST) [22] . Toxicity evaluation was done in all patients according to NCI CTC version 2.0 [23].
Follow up
Eligible patients were visited once a month after treatment starting, their PFS and overall survival (OS) time was recorded. Disease evaluation was performed every 3 months or when necessary. The time limit of follow-up was 18 months in present study.
Statistical analysis
Main objective of present study was to evaluate the safety and therapeutic effect of docetaxel weekly chemotherapy combined with RF hyperthermia for pretreated locally advanced non-small cell lung cancer. The primary end points were grade 3,4 hematological or non-hematological toxicities and PFS, the secondary end points were response rate, tumor control rate and OS.
Kaplan-Meier survival curve was used to describe PFS and OS. Statistical work was performed by soft ware SPSS 13.0 (SPSS Inc. USA). Lost patients were recorded as death, their PFS were calculated up to the last visit as well as OS, except they had already experienced tumor progression. 6 patients (20.7%) experienced a dose reduction to 30 mg/m 2 due to toxicities (5 patients due to neutropenia, 1 patient due to arthralgia).
Results
Patients' characteristics
Treatment delays were applied in 5 patients (17.2%), 4 delays occurred due to neutropenia, the other one occurred due to abnormal level of alanine aminotransferase (>2.5 × ULN).
3 patients (10.3%) experienced grade 1 empyrosis after heated, no related treatment was administered. This side effect released in 48 hours, not even one time of hyperthermia was delayed for this reason.
Main toxicities were summarized in Table 2 .
Response
There were 27 patients (93.1%) who had been evaluated for response. No patient achieved a complete remission (CR), 7 patients (25.9%) achieved a partial remission (PR), 11 patients (40.7%) were evaluated as a stable disease (SD), and 9 patients (33.3%) experienced a progression disease (PD). Overall response rate was 25.9%, tumor control rate (CR + PR + SD) was 66.6%.
Survival analysis
The median follow-up time was 16 months (range 12-18 months), 4 patients (13.8%) were lost at follow up, their PFS/OS (months) was recorded as following: 0/2, 0/2, 0/ 5, 0/7. Median PFS was 4 months (range 0-13 months, 95% CI: 1.9-6.1 months), one year progression free survival rate was 10.3% ( Figure 1 ). Median OS was 11 months (range 2-18 + months, 95% CI: 9.3-12.8 months), one year survival rate was 44.8% (Figure 2) . At the time of analysis, 5 patients were still alive. 
Discussion
Docetaxel is recommended for second-line chemotherapy of non-small cell lung cancer, and weekly administration regimen showed a good safety, but recent studies resulted that the response rate and survive was still poor [12] .
There are rare studies about hyperthermia for lung cancer, even it had been reported to improve the therapeutic efficacy in some drug insensitive tumors such as prostate cancer and soft tissue sarcoma [17, 18, 20] .
Structure of vascular in malignant tissue is great different from normal tissue, it was reported that the blood flow rate in normal tissue would be 30 times greater than tumor tissue [24] . This difference makes temperature of tumor tissue significantly higher than normal tissue under the same heat condition. Cytotoxic effect of several antitumor agents include docetaxel can be enhanced by raising temperature [25] . Hyperthermia also shows as a complementation of radiotherapy [26] . RF hyperthermia is powered by electromagnetic wave of a certain wavelength, it has the ability to go through whole human body and transforms to heat when different mediator encountered. Current study was designed to evaluate feasibility and efficacy of docetaxel plus RF hyperthermia for patients failed to response to prior platinum-containing chemotherapy.
A total of 29 eligible patients enrolled in present study, 12 patients were of stage IIIa, 17 patients were of stage IIIb. 21 patients (72.4%) completed the arranged study treatment, while 8 patients (27.6%) discontinued. Main hematological toxicity was neutropenia, 7 patients (24.1%) experienced Grade 3,4 neutropenia, most of them were grade 3. With G-CSF hypodermic injection, this toxicity was well controlled. None of grade 4 nonhematological toxicities was observed, but grade 3 nausea, transaminase increasing, arthralgia and myalgia had been observed. Only 3 patients experienced grade 1 empyrosis, and they all self-recovered. Results above showed the comparable toxicities [7, 11] , it might indicate that regional RF hyperthermia does not increase the toxicity of chemotherapy.
The therapeutic efficacy of the study treatment was acceptable, a response rate of 25.9% and a tumor control rate of 66.6% were better than docetaxel alone. A median PFS of 4 months and a median OS of 11 months might not be satisfied, but compared with docetaxel alone (median OS ranged from 6.4 to 9.2 months), these results were encouraging [7, 8] .
Conclusion
Docetaxel weekly regimen in conjunction with regional RF hyperthermia acted as the second-line treatment for pretreated locally advanced non-small cell lung cancer was safe and well tolerant. The results of current study also suggested advantages in response and survival. A further phase III study is supported by these results. Figure 2 Overall survival.
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